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Abstract
The brain-specific tyrosine phosphatase, STEP (STriatal-Enriched protein tyrosine Phosphatase) is 
an important regulator of synaptic function. STEP normally opposes synaptic strengthening by 
increasing N-methyl D-aspartate glutamate receptors (NMDARs) internalization through 
dephosphorylation of GluN2B and inactivation of the kinases ERK1/2 and Fyn. Here we show that 
STEP61 is elevated in the cortex in the Nrg1+/− knockout mouse model of SZ. Genetic reduction or 
pharmacological inhibition of STEP prevents the loss of NMDA receptors from synaptic 
membranes and reverses behavioral deficits in Nrg1+/− mice. STEP61 protein is also increased in 
cortical lysates from the CNS-specific ErbB2/4 mouse model of SZ, as well as in human induced 
pluripotent stem cell (hiPSC)-derived forebrain neurons and Ngn2-induced excitatory neurons 
from two independent SZ patient cohorts. In these selected SZ models, increased STEP61 protein 
levels likely reflect reduced ubiquitination and degradation. These convergent findings from 
mouse and hiPSC SZ models provide evidence for STEP61 dysfunction in SZ.
INTRODUCTION
STEP61, a membrane-associated phosphatase found in the postsynaptic density1 and 
endoplasmic reticulum2, is highly expressed in the frontal cortex and other forebrain 
regions3. STEP61 activity and degradation are tightly regulated through mechanisms that 
include inhibitory phosphorylation by PKA at a serine (ser221) within its substrate binding 
domain (kinase interacting domain; KIM)4 and degradation by the ubiquitin proteasome 
system (UPS)5. STEP61 is the only STEP isoform detected in the cortex and is elevated in 
several neuropsychiatric disorders, including fragile X syndrome (FXS)6, Parkinson’s 
disease (PD)7, and Alzheimer’s disease (AD)5 (reviewed in8, 9). The mechanisms for 
increased STEP61 include increased translation (FXS), disrupted ubiquitination (PD), and 
beta-amyloid-mediated inhibition of the proteasome (AD). Amelioration of the biochemical, 
cognitive and behavioral deficits through either genetic reduction or pharmacological 
inhibition of STEP activity in mouse models support a causal relationship between elevated 
STEP61 activity and these disorders 8, 10, 11.
We previously reported that STEP61 is elevated in postmortem anterior cingulate cortex and 
dorsolateral prefrontal cortex of SZ patients, as well as in mice treated with the 
psychotomimetics (and NMDAR antagonists) MK-801 and phencyclidine (PCP)12. 
Moreover, the acute (locomotor) and chronic (cognitive) effects of these psychotomimetics 
were blunted in STEP knock out (KO) mice12.
Here we investigated the extent and effect of STEP61 dysregulation in two genetic mouse 
models of SZ (Nrg1+/− and CNS-specific ErbB2/4 knockout mice13, 14) as well as in two 
independent cohorts of SZ human induced pluripotent stem cell (hiPSC)-derived neurons. 
We not only observed increased STEP61 activity in both genetic mouse models of SZ and 
the two cohorts of SZ hiPSC neurons, but also that STEP inhibition was sufficient to 
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ameliorate biochemical and behavioral deficits identified in these models. These results 
suggest a consistent and causally important contribution of STEP61 to SZ pathophysiology 
and thus identify it as a plausible therapeutic target.
MATERIALS AND METHODS
hiPSCs
SZ1: All SZ1 fibroblasts were obtained from Coriell (P1 [GM02038, male], P2 [GM01792, 
male], P3 [GM01835, female], P4 [GM02497, male]). Control fibroblasts were obtained 
from ATCC (C1 [CRL-2522, male]) and Coriell (C2 [GM03440, male], C3 [GM03651, 
female], C4 [GM04506, female], C5 [AG09319, female], C6 [AG09429, female]). SZ2: The 
Rapoport laboratory at NIH generously provided SZ2 fibroblasts from nine cases with 
childhood-onset-SZ and eight controls (C1 [NSB553, male], C2 [NSB690, male], C3 
[NSB2607, male], C4 [NSB3084, male], C5 [NSB3158, female], C6 [NSB3182, female], C7 
[NSB3234, male], C8 [NSB3113, female], P1 [NSB499, female], P2 [NSB581, male], P3 
[NSB676, female], P4 [NSB1442, male], P5 [NSB2513, male], P6 [NSB2620, male], P7 
[NSB2011, female], P8 [NSB2476, female], P9 [NSB2962, male]). CNV analysis (SZ115; 
SZ216) indicates that there is no evidence for any large deletion of NRG1 (or related genes) 
in either cohort. Detailed description of patients and demographic summary can be found in 
SI Methods and SI Tables 1 and 2.
SZ1: Human fibroblasts (HFs) were reprogrammed using doxycycline-inducible lentiviral 
vectors15. SZ2: HFs were reprogrammed using Cytotune Sendai virus (Life Technologies). 
All hiPSC lines were validated by: long-term expansion beyond ten passages; FACS analysis 
for SSEA-4 and TRA-1-60 levels; transcript analysis for OCT4, NANOG, c-MYC and 
LIN28; and to confirm normal karyotypes (SI Figure 5a-c). Detailed description can be 
found in SI Methods.
hiPSC forebrain neural progenitor cells (NPCs) were derived, expanded and differentiated 
using established methods (SZ1: as described15, 17; SZ2: as described18, 19 (detailed 
description can be found in SI Methods and validation SI Figure 5d). For Ngn2-induced 
neuronal differentiation, NPCs were transduced with a lentiviral TetO-mNgn2-T2A-PuroR 
(Addgene ID: 52047) together with a lentiviral constitutive reverse tetracycline 
transactivator (rtTA), (Addgene ID: 19780); transgene expression was induced with 
doxycycline (1 μg/ml; Sigma) for 7 days and selected with puromycin (1 μg/ml; Sigma) for 
24 h. Detailed description can be found in SI Methods.
Rat cortical neurons
All experimental procedures were approved by the Yale University Institutional Animal Care 
and Use Committee and in strict accordance with the NIH Guide for the Care and Use of 
Laboratory Animals. Primary cortical neurons were isolated from rat E18 embryos as 
described11, 20.
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Nrg1+/− mice were initially obtained from Mutant Mouse Regional Resource Centers 
supported by NIH (MMRRC Stock Number: 011745-UCD). Nrg1+/− mice were backcrossed 
with C57BL/6 mice (Jackson Laboratory). All mice were genotyped using PCR according to 
the vendor’s protocol. Brains from male Nrg1+/− mice and littermates were collected at 
several time points (1, 3, 6, 9 and 12 months). All mice were maintained at a controlled 
temperature and 12 h light/dark cycle with regular diet. Brain lysates from ErbB2/4 CNS KO 
mice (9 months) were prepared as described14 and were kindly provided by Dr. Müller.
For biochemical testing, one group of Nrg1+/− mice (male, 6-9 months) and WT littermates 
were administered intraperitoneally (i.p.) with vehicle (Veh, 0.1% DMSO in saline), 
clozapine (Clz, 1 mg/kg) or haloperidol (Hal, 2 mg/kg) daily for 2 weeks. A second group of 
Nrg1+/− and WT mice were administered acutely with vehicle (Veh, 0.1% DMSO in saline) 
or TC-2153 (10 mg/kg) and sacrificed 3 h post injections. Frontal cortices were collected for 
biochemical analyses.
Genetic and pharmacological testing was done in distinct experiments; independent 
measurements are most appropriately compared within, rather than between, these 
experiments. For genetic reduction of STEP, Nrg1+/− mice were crossed with STEP−/− mice 
(on C57BL/6 background as described12, 21 to produce Nrg1+/− mice null for STEP (double 
mutant); four cohorts was tested (6-9 months old, n = 9-16 each group). For pharmacologic 
reduction of STEP, mouse behavioral and cognitive assays were conducted on 4 cohorts of 
male Nrg1+/− and WT littermates (6-9 months old, n = 9-16 each group) were used. Detailed 
methodology can be found in the SI Methods.
Reagents and antibodies
Reagents are detailed in SI Methods. Antibodies are listed in SI Table 4. Primers are listed in 
SI Table 5.
Data analysis
For Western blotting, phosphorylated protein levels were normalized to total protein levels, 
then to β-actin as loading control, with one exception: when pGluN2B was evaluated in 
synaptosomal fractions (P2), pGluN2B levels were normalized to β-actin directly. All data 
were expressed as means ± SEM and statistical analyses were performed using SPSS 
Statistics 19 (IBM, New York, NY), Prism 6.0 (GraphPad Software, La Jolla, California) or 
JMP10 (SAS Institute Inc., Cary, North Carolina). Significance (P < 0.05) was determined 
by two-way analysis of variance (ANOVA) with post-hoc Bonferroni test. For locomotion, 
data were analyzed with two-way ANOVA with repeated measures, with post-hoc 
Bonferroni or paired t-test. A Chi-square one-sample t-test against 50% chance was used for 
social dominance tube test. For both SZ1 hiPSC studies (1-2 independent NPC lines were 
used per hiPSC, 1 hiPSC per individual (see SI Table 1)) and SZ2 hiPSC experiments (1 
NPC line per hiPSC, 1 hiPSC per individual (see SI Table 2)), error bars represent variation 
(standard error) between parallel differentiations from the same NPC line.
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STEP61 is elevated in Nrg1+/−, CNS-specific ErbB2/4 knockout mice and hiPSC neurons 
from SZ patients
NRG113, 22, 23 and ERBB424 have been linked to SZ (reviewed in25); either reduction or 
overexpression of Nrg1 signaling results in behavioral and cognitive deficits in animal 
models13, 26-28. To investigate the functional implications of STEP61 dysregulation in SZ, 
we analyzed STEP61 protein levels in Nrg1+/− and CNS-specific ErbB2/4 knockout 
mice13, 14. Total STEP61 was increased whereas the phosphorylated (inactive) form of 
STEP61 was decreased in synaptosomal fractions (P2) from frontal cortex of Nrg1+/− mice 
(Figure 1a). Phosphorylation of STEP61 substrates GluN2B and ERK1/2, as well as synaptic 
levels of GluN2B, were decreased in P2 fractions (Figure 1a) in the presence of increased 
STEP61. Analysis of the ratio of synaptic GluN2B versus total GluN2B also revealed a 
decrease in functional receptors in synaptic membranes (Figure 1a). There was a 
developmental increase in STEP61 levels in Nrg1+/− mice starting at 3 months of age (SI 
Figure 1a). A similar significant increase in STEP61 was observed in ErbB2/4 CNS-specific 
knockout mice, another putative SZ model, with a decrease in the Tyr phosphorylation of 
GluN2B and ERK1/2 (SI Figure 1b).
We next examined a cohort of 6 controls and 4 SZ patients (herein referred to as cohort SZ1: 
available clinical information described in SI Table 1, originally described 15, 17), from 
which we had previously reprogrammed hiPSCs, differentiated hiPSC-derived neurons and 
reported synaptic deficits15, 29. Gene expression comparisons of our hiPSC forebrain (FB) 
neuron populations to the Allen BrainSpan Atlas indicate that these cells, from both controls 
and SZ patients, resemble fetal rather than adult brain tissue, particularly the cortical and 
subcortical forebrain regions 17. FB neuron populations are comprised of ~80% neurons and 
~20% astrocytes 15; moreover, the majority of FB neurons are VGLUT1-positive, and so are 
presumably glutamatergic, although approximately 30% are GAD67-positive (GABAergic) 
and a small minority are TH-positive (dopaminergic) 15, 17.
Perturbations in the GluN2A/GluN2B subunit ratio (encoded by the GRIN2A and GRIN2B 
gene) are thought to reflect synaptic deficits30. Over the course of hiPSC FB neuronal 
differentiation, GluN2A expression increases with no change in GluN2B, resulting in an 
increased GluN2A/GluN2B mRNA ratio (SI Figure 2a). SZ1-FB neurons had a decreased 
GluN2A/GluN2 mRNA ratio (decreased expression of GluN2A while GluN2B was 
unchanged15, 17, 31) (SI Figure 2b) and a decreased GluN2A/GluN2B protein ratio 
(decreased GluN2A protein in SZ1 FB neurons with no significant change in GluN2B 
protein levels) (SI Figure 2c-e).
We observed a significant increase of total STEP61 (tSTEP61) and active, non-
phosphorylated STEP61 (aSTEP61) in SZ1-FB hiPSC neurons. Data are presented both by 
group average (Figure 1b) and by individuals (SI Figure 3). Increased STEP61 was 
associated with decreased phosphorylation of GluN2B (Figure 1b; SI Figure 3c) and 
ERK1/2 (Figure 1b; SI Figure 3d) at the sites dephosphorylated by STEP. We also measured 
STEP61 levels in patient fibroblasts, in patient-derived pluripotent hiPSCs, and in replicating 
hiPSC-derived NPCs. STEP61 protein was not detected in fibroblast cultures and, although 
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present, showed no increase in SZ hiPSCs (SI Figure 4a, b) or NPC cultures (SI Figure 4c, 
d). These results indicate that the increase in STEP61 is only detectable in post-mitotic SZ1-
FB hiPSC neurons.
To validate these findings, we established a second cohort of SZ hiPSCs, comprising eight 
controls and nine SZ patients (herein referred to as SZ2: available clinical information 
described in SI Table 2; FACS validation for all hiPSCs (TRA-1-60 and SSEA4) and NPCs 
(NESTIN and SOX2) is shown in SI Figure 5; partially reported 19). Consistent with our 
observations from SZ1, SZ2-FB hiPSC neurons showed increased total STEP61 (Figure 1c; 
SI Figure 6a) and active STEP61 (Figure 1c; SI Figure 6b), which correlated with decreased 
phosphorylation of GluN2B (Figure 1c; SI Figure 6c) and ERK1/2 (Figure 1c; SI Figure 6d). 
Moreover, because SZ2 hiPSCs were not generated using tetracycline-inducible methods, we 
were also able to apply a well-established Ngn2-induction method to yield populations of 
nearly pure excitatory (SZ2-GLU) neurons (SI Figure 7)32, 33; critically, these Ngn2-induced 
GLU populations show no evidence for including GABAergic or dopaminergic 
neurons32, 33. SZ2-GLU hiPSC neurons showed increased total (Figure 1d; SI Figure 8a) 
and active (Figure 1d; SI Figure 8b) STEP61 levels, which again correlated with decreased 
phosphorylation of GluN2B (Figure 1d; SI Figure 8c) and ERK1/2 (Figure 1d; SI Figure 
8d), indicating that increased STEP61 could be specifically detected in defined populations 
of excitatory neurons derived from patients with SZ. Increased STEP61 levels were driven by 
a subset of patients (a one-sample two-tailed t-test found that 3 of 4 of SZ1-FB, 4 of 9 of 
SZ2-FB and 3 of 9 of SZ2-GLU neuron samples tested showed evidence of elevated STEP61 
levels) (SI Table 3). Increased STEP activity in SZ2 GLU neurons in no way excludes the 
possibility that STEP levels are also perturbed in other neuronal or glial cell populations.
Genetic reduction of STEP61 increases phosphorylation of STEP targets in Nrg1+/− mice 
and hiPSC neurons
Nrg1+/− mice null for STEP61 (double mutant, DM) showed restored tyrosine 
phosphorylation levels of GluN2B and ERK1/221, 34 (Figure 1e). Genetic reduction of STEP 
in Nrg1+/− mice also rescued functional GluN2B-containing receptors at synaptic sites, as 
measured by synaptic versus total receptor levels (Figure 1e). Similarly, STEP61 knockdown 
in hiPSC-derived neurons using lentiviral (LV)-short hairpin RNA (shRNA) reduced total 
(Figure 1f) and active (Figure 1g) STEP61 levels in SZ1-FB hiPSC neurons, and increased 
phosphorylation of pGluN2B (Figure 1h) and pERK1/2 (Figure 1i).
Pharmacological inhibition of STEP increases phosphorylation of STEP targets in Nrg1+/− 
mice and hiPSC neurons
Several neuroleptics including clozapine, risperidone, and haloperidol are known to result in 
inhibitory phosphorylation of STEP61 by PKA12. To test whether antipsychotic treatment 
was sufficient to reduce elevated STEP61 activity in Nrg1+/−mice, WT mice were 
administered vehicle (Veh), clozapine (Clz, 1 mg/kg, i.p.) or haloperidol (Hal, 2 mg/kg, i.p.) 
daily for 3 weeks. Indeed, Western blot analysis of P2 fractions demonstrated that in WT 
mice, neuroleptic treatment decreased STEP61 activity without changing total STEP61 levels, 
leading to an overall increase in the phosphorylation of STEP61 substrates (Figure 2a). 
Similarly, neuroleptic treatment decreased STEP61 activity without changing total STEP61 
Xu et al. Page 6













levels in Nrg1+/− mice, leading to an overall increase in the phosphorylation of STEP61 
substrates, often above baseline WT levels (Figure 2a). These observations are in agreement 
with a previous finding that clozapine restores the tyrosine phosphorylation of GluN2B at 
Tyr1472 in Nrg1+/−mice35. In both control and SZ1-FB hiPSC neurons, we similarly 
observed that 7-day treatment with clozapine (5 μM) or loxapine (10 μM) decreased STEP61 
activity and increased the phosphorylation GluN2B and ERK1/2, without affecting total 
STEP61 levels (Figure 2b).
We recently characterized the dose-responses, time kinetics and specificity of a novel 
inhibitor of STEP [8-(trifluoromethyl)-1,2,3,4,5-benzo pentathiepin-6-amine hydro-
chloride], known as TC-2153 11. TC-2153 showed relative specificity for STEP61, 
selectively inhibiting STEP in the cortex and hippocampus, but not two other closely related 
PTPs (i.e. PTP-SL in cerebellum and HePTP in spleen) 11. It also reversed the biochemical 
and cognitive deficits in a mouse model of AD11, a disorder also characterized by a 
significant elevation of cortical and hippocampal STEP61 levels10. TC-2153 treatment of 
both WT and Nrg1+/− mice produced increased tyrosine phosphorylation of GluN2B and 
ERK1/2 (Figure 2c). TC-2153 also inhibited STEP61 activity in control and SZ1-FB hiPSC 
neurons, without changing total STEP61 levels (Figure 2d). Treatment of control and SZ1-
FB hiPSC neurons with 1 μM TC-2153 led to an increase in the Tyr phosphorylation of 
pGluN2B and pERK1/2 (Figure 2d) that was comparable to clozapine or loxapine treatment 
(Figure 2b).
STEP inhibition increases spontaneous neuronal activity in control and SZ1-FB hiPSC 
neurons
We tested the effect of chronic 1 μM TC-2153 treatment for 7 or 14 days on spontaneous 
neuronal activity in control and SZ1-FB hiPSC neurons using multi-electrode array (MEA) 
recordings. In two of the three SZ1 patients with elevated STEP61 activity (see SI Figure 3 
for relative STEP61 levels in each patient), 14 days of administration with TC-2153 was 
sufficient to significantly increase the rate of neuronal firing in cells from these patients 
(Figure 3a, b). For one of the patients this was also true in the presence of acute (30 min) 
treatment with 50 μM picrotoxin, a non-competitive channel blocker for the GABAA 
receptor, indicating that changes resulting from TC-2153 may reflect changes to the 
glutamatergic network (Figure 3c-e).
STEP inhibition reverses behavioral and cognitive deficits in Nrg1+/− mice
We tested whether TC-2153 could reverse the behavioral and cognitive deficits in Nrg1+/− 
mice, which show increased locomotion and disrupted working memory and cognition13, 28. 
First, we tested whether TC-2153 was effective in reversing PCP-induced hyperlocomotion 
in WT and Nrg1+/− mice. Following PCP administration (7.5 mg/kg, i.p.), a two-way 
ANOVA with repeated measures analysis demonstrated significant main effects of Time [5 
min bin: F(17,952) = 52.35, P < 0.0001], Group [4 groups: F(3,56) = 7.87, P < 0.001] and a 
Time × Group interaction [F(51,952) = 1.78, P < 0.001]. Bonferroni’s post hoc test showed 
significant attenuation of PCP-induced hyperlocomotion in Nrg1+/− mice by TC-2153 (P < 
0.01, compared to Veh-treated Nrg1+/− mice) (Figure 4a). Two-way ANOVA analysis of 
total distance traveled showed that there were significant effects of Treatment [Veh or 
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TC-2153, F(1,54) = 20.73, P < 0.001] and Genotype [WT or Nrg1+/−, F(1,54) = 4.92, P < 
0.05]. Bonferroni’s post hoc test also revealed that TC-2153 led to a significant attenuation 
of PCP-induced hyperactivity in Nrg1+/− mice (P < 0.01, compared to Veh/ Nrg1+/− group 
(Figure 4b). In addition, pretreatment of Veh or TC-2153 had a significant effect on 
stereotypies (such as sniffing, rearing and grooming) [F(1,55) = 21.67, P < 0.001] and there 
was a significant main effect of Genotype [WT or Nrg1+/−, F(1,55) = 6.90, P < 0.05]. 
Bonferroni’s post hoc test revealed TC-2153 also attenuated PCP-induced stereotypies in 
Nrg1+/− mice (P < 0.01) (Figure 4c). TC-2153 (10 mg/kg, i.p.) also normalized locomotor 
activity in the open field (SI Figure 9a, b). Next we tested WT and Nrg1+/− mice in the Y-
maze task. We found no difference in arm alternation in these mice (SI Figure 9c). However, 
we found Nrg1+/− mice made more arm entries indicating that Nrg1+/− mice were 
hyperactive in the Y-maze. Administration of TC-2153 reversed hyperactivity in the Y-maze 
(Figure 4d). Two-way ANOVA analysis of arm entries showed that there were significant 
effects of Treatment [Veh or TC-2153, F(1,53) = 7.27, P < 0.01] and Genotype [WT or 
Nrg1+/−, F(1,53) = 9.35, P < 0.01]. Bonferroni’s post hoc test showed that TC-2153 reduced 
arm entries in Nrg1+/− mice (P < 0.05, compared to Veh/ Nrg1+/− group (Figure 4d). 
Furthermore, TC-2153 reduced aggression in Nrg1+/− mice (Figure 4e), and significantly 
improved social behavior in a social novelty task (Figure 4f, g).
Because the motor abnormalities observed in Nrg1+/− mice (Fig 4a-c; SI Fig 9 a, b) may 
confound social behavioral measures, we next conducted a number of non-motor behavioral 
assays. Mice with deficits in Nrg1 signaling have been reported to show deficits in prepulse 
inhibition (PPI)36, 37; we observed deficits in PPI in Nrg1+/− mice (SI Figure 9n). Repeated-
measure ANOVA analyses revealed that TC-2153 normalized PPI (Figure 4h) with main 
effects of Treatment [Veh or TC, F(1,18) = 11.43, P < 0.001], Interval [30 ms or 100 ms, 
F(1, 18) = 13.71, P < 0.001] and Intensity [+6 db, +12 db or +16 db, F(2,17) = 3.67, P < 
0.05]. TC-2153 treatment did not alter PPI in WT mice (SI Figure 9o). There was no 
difference in startle response in the different treatment groups (SI Figure 9p). TC-2153 also 
improved the ability of Nrg1+/− mice to distinguish between novel and familiar objects in the 
novel object recognition task (Figure 4i). Clozapine (1 mg/kg, i.p.), which served as a 
positive control, had similar significant effects in all tasks (SI Figure 10).
Our previous findings 12, 38 suggested that genetic reduction of STEP was sufficient to 
reduce the biochemical and behavioral changes induced by the NMDAR antagonist PCP. To 
further demonstrate that pharmacological inhibition of STEP was sufficient to ameliorate the 
behavioral effects arising from NMDAR antagonism, we used another NMDAR blocker, 
MK-801, which has been widely validated as a pharmacological model of SZ and induces 
motor and cognitive deficits in mice 39-41. In agreement with previous reports 42, 43, we 
found MK-801 treatment induced hyperactivity (SI Figure 11a-c) and memory deficits in the 
Y-maze and novel object recognition tasks (SI Figure 11d, e); these deficits were 
significantly reversed by pretreatment with TC-2153 (SI Figure 11a-e). While MK-801 led 
to reduced GluN2B/GluN1 in synaptosomal membranes (P2) and decreased phosphorylation 
of ERK1/2, this was completely rescued by TC-2153 (SI Figure 11f).
We tested whether genetic reduction of STEP61 in Nrg1+/− mice would recapitulate the 
effects of TC-2153. Nrg1+/− mice were hyperactive in the open-field test; this hyperactivity 
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was reduced in DM mice (SI Figure 12a, b). Nrg1+/− hyperactivity after PCP administration, 
was significantly reduced in DM mice (SI Figure 12c-e). In the social dominance task, 
aggressiveness in Nrg1+/− mice was normalized in DM mice (SI Figure 12f). In a Y-maze 
test of working memory, Nrg1+/− mice were normal in terms of alternation choices (SI 
Figure 10c), but made significantly more arm entries; this was normalized in DM mice (SI 
Figure 12g, h). In the novel object recognition task, Nrg1+/− mice failed to distinguish 
between novel and familiar objects, while DM mice behaved similarly to WT mice (SI 
Figure 12i). Finally, deficient social recognition in Nrg1+/− mice was normalized in DM 
mice (SI Figure 13). Taken together, these experiments establish that both genetic reduction 
and pharmacological inhibition of STEP attenuate the biochemical, behavioral and cognitive 
deficits in Nrg1+/− mice.
NRG1 signaling leads to ubiquitination and degradation of STEP61 in rat cortical neurons 
and hiPSC neurons
STEP61 mRNA levels were not different in SZ1-FB hiPSC neurons as measured using 
quantitative real-time PCR (SI Figure 14a), suggesting that increased transcription of STEP 
does not contribute to the elevation of STEP61 protein levels in these neurons. Likewise, 
there was no detectable increase in STEP61 mRNA in Nrg1+/− mice (SI Figure 14b).
Because STEP61 is normally regulated by the UPS, a process that is disrupted in SZ12, PD7 
and AD mouse models10, 44, we tested the hypothesis that disruption of STEP61 
ubiquitination contributed to the elevated STEP61 levels seen in our several SZ models. We 
observed decreased ubiquitination of total STEP61 in SZ1-FB hiPSC neurons (Figure 5a), 
SZ2-FB hiPSC neurons (Figure 5b), and SZ2-GLU hiPSC neurons (Figure 5c). There was a 
general decrease of ubiquitinated proteins (SI Figure 15a) and perturbed levels in some 
(UBE2N, UBA6) UPS proteins in SZ1-FB hiPSC neurons (SI Figure 15c, e, g, i, k). 
Similarly, we observed decreased ubiquitination of total STEP in frontal cortex from 
Nrg1+/− mice (Figure 5d). Here, while we did not observe a general decrease of 
ubiquitinated proteins (SI Figure 15b) or perturbations in most UPS proteins (SI Figure 15d, 
f, h, j, l), there was again a disruption of UBE2N levels (SI Figure 15d) in Nrg1+/− mice.
We next asked if NRG1 signaling regulates STEP61 levels. NRG1β-treatment of WT rat 
cortical neurons (10 nM, 30 min) led to decreased STEP61 levels; this was blocked by 
PD158780, a pan-ErbB receptor antagonist (Figure 5e). Concomitant with decreased 
STEP61, there was increased tyrosine phosphorylation of GluN2B and ERK1/2 (Figure 5e) 
and increased surface levels of GluN2B and GluN1, all blocked by PD158780 (Figure 5f). 
The GABAA receptor, which is not a STEP61 substrate, showed no changes following 
NRG1β treatment (Figure 5f). The NRG1β extracellular domain (ECD) (50 ng/kg, i.p.) 
crosses the brain-blood barrier and is an effective activator of NRG1 signaling45-47. When 
injected into Nrg1+/− mice (i.p.) daily for 5 consecutive days, NRG1β ECD led to a 
significant reduction of STEP61 and an increase in the tyrosine phosphorylation of the 
STEP61 substrates GluN2B and ERK1/2 (Figure 5g). Similarly, NRG1β-treatment of control 
and SZ1-FB hiPSC neurons resulted in a significant reduction of STEP61 and an increase in 
the tyrosine phosphorylation of GluN2B and ERK1/2 (Figure 5h).
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Finally, we examined whether NRG1 signaling can directly affect STEP61 ubiquitination. 
NRG1β-treatment (10 nM, 30 min) of WT rat cortical neurons increased ubiquitination 
(Figure 5i) and proteasome-dependent degradation (Figure 5i) of STEP61. Although STEP61 
can be proteolysed by calpain after excitotoxic conditions20, inhibition of calpain, caspase 
and lysozyme demonstrated that they were not involved in STEP61 degradation (SI Figure 
16). We repeated these experiments in SZ1-FB hiPSC neurons and assayed levels of STEP61 
ubiquitination after NRG1β treatment. Consistent with our observations in rodents, NRG1β 
treatment increased STEP61 ubiquitination and degradation in both control and SZ1-FB 
hiPSC neurons (Figure 5j).
DISCUSSION
Here we demonstrate that STEP61 protein levels are elevated in two mouse models of SZ 
(Nrg1+/− and CNS-specific ErbB2/4 knockouts) as well as two populations of hiPSC-derived 
(FB and GLU) neurons from two independent cohorts of SZ patients (similarities and 
discrepancies between the mouse and human models are summarized in SI Table 6). Genetic 
or pharmacologic reduction of STEP61 activity in both mouse and hiPSC-based SZ models 
increased the phosphorylation of STEP targets, altered neuronal activity and ameliorated 
cognitive and behavioral deficits. These results reveal a convergence of mouse and hiPSC 
studies, consistent with our previously reported post-mortem data12 (although see48). 
Elevated STEP61 levels were driven by a subset (~50%) of our SZ1- and SZ2- hiPSC 
neurons; our results must next be replicated across larger cohorts of SZ patients, in order to 
better define the subset of patients with increased STEP61 levels. We predict that, 
particularly for these individuals, STEP61 inhibitors might be effective therapeutic agents.
Our mouse and hiPSC findings are consistent with the glutamate hypothesis of SZ (reviewed 
in49-51); Nrg1 signaling is a critical mediator of synaptic function and plasticity in 
glutamatergic signaling (reviewed in 25) and Nrg1+/− mice have been reported as having 
mEPSCs with faster decay and a smaller NMDA/AMPA ratio than wild-type littermates52. 
Deletion of ErbB4, the Nrg1+/− receptor, results in reduced frequency and amplitude of 
mEPSCs53. Finally, given that recombinant STEP protein decreased NMDAR currents and 
mEPSCs 1, while functional inhibition 1 or genetic deletion of STEP 10 enhanced mEPSCs, 
and that activity-dependent regulation of STEP contributes to homeostatic stabilization of 
both NMDAR and AMPAR excitatory synapses 54, it is possible that perturbations in 
STEP61 contribute to glutamatergic dysfunction both in mouse models of SZ and in patients. 
Nonetheless, this hypothesis needs to be investigated at the circuit-level in mouse models 
and confirmed by electrophysiology in hiPSC neurons.
Because genomic analyses have not linked variants at PTPN5 (the gene encoding the protein 
STEP) to SZ, we posit that increased STEP61 activity is a downstream biochemical 
consequence of other perturbations, rather than a primary cause of SZ. Increased STEP61 
levels seem to derive from disruptions in the ubiquitination and degradation of STEP61, 
which are regulated, at least in part, by NRG1 signaling. This is consistent with evidence 
that genes involved in UPS are down-regulated in postmortem SZ cortical tissue55, 56, and 
similar to what is observed in neurodegenerative diseases5, 7, 57. While further work will 
clarify whether other mechanisms also affect STEP61 protein levels, our findings suggest 
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that inhibition of STEP61 activity might prove to be a promising point of therapeutic 
intervention for the subset of SZ patients in which STEP61 levels are increased.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. STEP61 level is elevated in Nrg1
+/− mice and hiPSC neurons from SZ patients
(a) STEP61 level is elevated in Nrg1+/− mice. P2 membrane fractions from 9-month-old 
Nrg1+/− mice were processed by western blotting (WB) using antibodies against total 
STEP61, phosphorylated STEP61 (pSTEP61, inactive) and tyrosine phosphorylation of STEP 
substrates GluN2B and ERK1/2. All antibodies are listed in SI Table 4. (b-d) STEP61 level 
is elevated in SZ patients-derived neurons. Total STEP61 (tSTEP61), active STEP61 
(aSTEP61) and Tyr phosphorylation of STEP substrates (GluN2B and ERK1/2) levels were 
probed in SZ1 forebrain (FB) neurons (b), SZ2-FB hiPSC neurons (c) and SZ2 Ngn2-
induced excitatory (GLU) neurons (d). Detailed description of patients and demographic 
summary can be found in SI Methods and SI Tables 1 and 2 (e) Tyr phosphorylation of 
STEP substrates is restored in Nrg1+/− mice null for STEP. P2 fractions from wild type 
(WT), Nrg1+/−, STEP−/− and Nrg1+/− STEP−/− (double mutant, DM) mice were processed 
by WB and probed for targets shown in the figure. (f-i) STEP LV-shRNA knockdown (KD), 
relative to LV-scrambled control (Ctl), resulted in significantly decreased tSTEP61 (f) and 
aSTEP61 (g) levels and increased phosphorylation of the STEP61 substrates pGluN2B (h) 
and pERK1/2 (i) in SZ1-FB hiPSC neurons. Mice data were expressed as mean ± SEM and 
statistical significance was determined using one-way ANOVA with Bonferroni test (*P < 
0.05, **P < 0.01, n = 6 each group). hiPSC neuron data were expressed as mean values from 
3-6 replicates and statistical significance was determined by nested ANOVA analyses (*P < 
0.05, **P < 0.01, SZ1-FB: 6 controls and 4 patients; SZ2-FB and SZ2-GLU: 8 controls and 
9 patients).
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Figure 2. Pharmacological inhibition of STEP61 restores NMDAR biochemical signaling in 
Nrg1+/− mice and hiPSC neurons
(a) Antipsychotics administration leads to inactivation of STEP61 and increases in Tyr 
phosphorylation of GluN2B and ERK1/2 in vivo. WT and Nrg1+/− mice were administered 
clozapine (Clz, 1 mg/kg, i.p.), haloperidol (Hal, 2 mg/kg, i.p.) or vehicle (Veh) daily for 2 
weeks. Changes in phosphorylation of STEP61 and its substrates in P2 fractions were 
analyzed by WB. (b) Antipsychotics clozapine (Clz, 5 μM) and loxapine (Lox 10 μM) 
resulted in phosphorylation and inactivation of STEP61 and subsequent increases in Tyr 
phosphorylation of GluN2B and ERK1/2 in control and SZ1-FB hiPSC neurons. (c) WT and 
Nrg1+/− mice were administered TC-2153 (TC, 10 mg/kg, i.p.) or vehicle (Veh) acutely for 3 
h. P2 fractions were used to probe for STEP and its substrates on WB. Mice data were 
expressed as mean ± SEM and statistical significance was determined using one-way 
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ANOVA with Bonferroni test (*P < 0.05, **P < 0.01, #P < 0.05 compared with Nrg1+/− Veh 
group, n = 6 each group). (d) TC-2153 treatment leads to significantly increased pGluN2B 
and pERK1/2 levels in control and SZ1-FB hiPSC neurons, without altering tSTEP61 or 
aSTEP61 levels. hiPSC neuron data were expressed as mean values from 3-6 replicates and 
statistical significance was determined by nested analyses using JMP (*P < 0.05, **P < 0.01, 
SZ1-FB: 6 controls and 4 patients).
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Figure 3. STEP inhibitor increases spontaneous neuronal activity in hiPSC neurons
(a) Multi-electrode array (MEA) analysis reveals that treatment with TC-2153 (1 μM), for 
either the final 7 or 14 days of differentiation, increased the rate of spontaneous neuronal 
firing in SZ1-FB hiPSC neurons from the 2 patients with most elevated STEP61 levels. (b) 
Representative raw MEA cumulative neuronal spike activity showing the effect of TC-2153 
(1 μM) on SZ1-FB hiPSC neurons. (c) Acute pharmacological inhibition of SZ1-FB hiPSC 
neurons with picrotoxin (PTX) (30 min, 50 μM), when combined with MEA analysis, 
reveals that chronic TC-2153 (1 μM) treatment (7 or 14 days) affects firing of excitatory 
neurons. (d) MEA analysis of one control hiPSC line, showing that acute PTX (50 μM) 
treatment for 30 minutes results in decreased neuronal spiking, but when combined with 
chronic TC-2153 treatment (7 or 14 days), neuronal activity is increased compared to PTX 
treatment alone. (e) Representative raw MEA traces of neuronal activity showing the effect 
of TC-2153 (1 μM), in the presence of PTX (50 μM), on control hiPSC neurons. For all 
experiments, in each condition, 6 replicates per NPC line were tested (*P < 0.05, One-way 
ANOVA with Fisher’s post-hoc, SZ1-FB: 6 controls and 4 patients).
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Figure 4. STEP inhibition reverses behavioral and cognitive deficits in Nrg1+/− mice
Male WT and Nrg1+/− littermates (6-9 months old, 9-16 male mice each group) were used 
for all tests. (a-c) Pharmacological inhibition of STEP61 normalizes PCP-induced 
hyperlocomotor activity and stereotypies. Mice were administered TC-2153 (TC, 10 mg/kg, 
i.p.) or vehicle (Veh), and monitored for basal activities for 30 min. Mice were then 
challenged with PCP (7.5 mg/kg, i.p.) for 1 h. Distance traveled in each 5 min bin during the 
90 min test period (a), total distance traveled (b) and total stereotypic counts (c) were 
recorded and analyzed using Activity Monitor (MED Associates). (d) Nrg1+/− mice made 
more entries in Y-maze; this was reversed 3h after TC-2153 treatment. (e) TC-2153 
administration normalizes aggressive behavior in Nrg1+/− mice. Mice were administered 
TC-2153 (TC, 10 mg/kg, i.p.) or vehicle (Veh). Three h after injection, mice were tested in a 
narrow plastic tube against non-littermate naïve WT mice. Each mouse went through 4 trials 
and % win was plotted. (f, g) TC-2153 administration improves social behavior in the social 
novelty task in Nrg1+/− mice. Mice were administered TC-2153 (TC, 10 mg/kg, i.p.) or 
vehicle (Veh). Three h after injection, mice were tested in 3-chamber social task. Behaviors 
in the first two stages (habituation and social preference) are shown in SI Figure 10. (h) 
TC-2153 treatment reversed PPI deficits in Nrg1+/− mice. Nrg1+/− mice were treated with 
TC or vehicle 3 h prior to PPI test. (i) TC-2153 reverses cognitive deficits in Nrg1+/− mice in 
the novel object recognition (NOR) task. Mice were administered TC-2153 (TC, 10 mg/kg, 
i.p.) or vehicle (Veh). Three h after injection, mice were trained with two identical objects. 
Twenty-four h post training; mice were tested in the choice phase with one familiar object 
and one novel object. All data were expressed as mean ± SEM and statistical significance 
was determined using two-way ANOVA with repeated measures followed by post hoc 
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Bonferroni test for (a) or two-way ANOVA with post hoc Bonferroni test for (b-d) or 
repeated-measure (RM)-ANOVA for (h) or Chi-square one-sample t-test against 50% chance 
for (e) or Student t-test comparing two objects (f, g, i) (*P < 0.05, **P < 0.01, compared 
with WT Veh group; ##P < 0.01 compared with Nrg1+/− Veh group, n = 9-16 per group).
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Figure 5. NRG1 signaling leads to ubiquitination and degradation of STEP61 in rat cortical 
neurons and hiPSC neurons
(a-c) Ubiquitination of STEP is decreased in SZ hiPSC neurons. Ubiquitinated protein were 
pulled down from SZ1-FB hiPSC neurons (a), SZ2-FB hiPSC neurons (b) or SZ2-GLU 
hiPSC neurons (c) using tandem ubiquitin binding entities (TUBE) agarose beads as 
described in the SI Methods, followed by detecting using anti-STEP antibody. (d) 
Ubiquitination of STEP is decreased in Nrg1+/− mice. Male WT and Nrg1+/− mice (9 months 
old) were used to isolate ubiquitinated STEP using TUBE. (e) NRG1β treatment results in 
decreased STEP61 level and increased Tyr phosphorylation of GluN2B and ERK1/2 in 
cultures. Rat cortical neurons (DIV 14) were pretreated with vehicle (0.1% DMSO) or pan-
ErbB receptor antagonist (PD158780, 10 μM) for 30 min, followed by NRG1β (10 nM) for 
30 min. Neuronal lysates were analyzed for STEP61, pSTEP61 and tyrosine phosphorylation 
of STEP substrates. (f) NRG1β treatment leads to increased surface NMDARs in cultures. 
Cortical neurons were treated with NRG1β (10 nM) for 30 min. Cells were incubated with 
1.5 mg/ml Sulfo-NHS-SS-Biotin for 20 min at 4°C, lysed in 1xRIPA buffer. Equal amount 
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of lysates (300 μg) was incubated with NeutrAvidin agarose to isolate biotinylated proteins 
including surface receptors. Total lysates were used to measure total protein levels. (g) 
NRG1β administration normalizes STEP61 level and restored Tyr phosphorylation of 
GluN2B and ERK1/2 in Nrg1+/− mice. Male WT and Nrg1+/− littermates (6-9 months old) 
were administered vehicle (saline) or NRG1β ECD (50 ng/kg, i.p.) daily for 5 days. Frontal 
cortices were collected 3 h after the last injections and P2 fractions were used for 
biochemical analysis. (h) NRG1β treatment results in decreased STEP61 level and increased 
Tyr phosphorylation of GluN2B and ERK1/2 in human neurons. SZ1-FB and control 
neurons were treated with NRG1β (10 nM) for 6 h. STEP61 and phosphorylation of STEP 
substrates were assessed on WB. (i) NRG1 signaling leads to increased ubiquitination of 
STEP61 in rat cortical neurons. Cultures were pretreated with MG-132 (10 μM) for 1 h, 
followed by NRG1β treatment (10 nM, 30 min). All STEP species were immunoprecipitated 
using anti-STEP antibody and probed with anti-ubiquitin antibody. (j) NRG1β treatment 
leads to increased ubiquitination of STEP61 in human neurons. SZ1-FB and control neurons 
were pretreated with MG-132 (10 μM, 1 h), followed by NRG1β treatment (10 nM, 6 h). 
Ubiquitinated STEP species were pulled down using TUBE and detected by anti-STEP 
antibody. All data were expressed as mean ± SEM and statistical significance was 
determined using one-way ANOVA with Bonferroni test (*P < 0.05, **P < 0.01, n = 6 each 
group).
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